8-K: Earth Science Tech Engages Hayden IR, Reports Strong H1 2026

Earth Science Tech, Inc. announced its engagement with Hayden IR to enhance investor relations, following a strong first half of fiscal 2026 with $17.8 million in revenue and 70%+ gross margins.

Summary

• Earth Science Tech, Inc. (ETST) has engaged Hayden IR, a nationally recognized investor relations and capital markets communications firm, to bolster investor outreach, communications strategy, and market awareness.
• The engagement follows ETST's successful completion of its FINRA 15c-211 clearance, establishing a firm regulatory foundation.
• For the first half of fiscal 2026, ETST reported $17.8 million in revenue, $1.4 million in net income, and $1.18 million in operating cash flow.
• The company achieved gross margins exceeding 70% during this period, demonstrating a robust business model.
• CEO Giorgio R. Saumat holds over 122 million shares, acquired entirely with cash, indicating strong management alignment with shareholder interests.
• ETST operates as a strategic holding company with diverse subsidiaries in compounding pharmaceuticals (RxCompoundStore.com, Mister Meds), telemedicine (Peaks Curative, DOConsultations, Las Villas Health Care), real estate development (Avenvi), and direct-to-consumer retail (MagneChef).
• Avenvi, a wholly-owned subsidiary, manages investment activities for ETST and oversees the company's ongoing $10 million share repurchase program.

Sentiment

Score: 8

Explanation: The filing presents strong financial performance for H1 2026, including high revenue, net income, operating cash flow, and gross margins. The strategic engagement with a reputable investor relations firm and the CEO's significant shareholding indicate a proactive approach to value creation and strong management alignment. The only minor negative is the implication of unoptimized operating leverage, which is also framed as a future opportunity.

Positives

• Engagement with Hayden IR is expected to significantly improve investor outreach, communication strategy, and market awareness.
• Successful completion of FINRA 15c-211 clearance establishes a strong regulatory foundation for capital market activities.
• Robust financial performance in H1 fiscal 2026, with $17.8 million in revenue, $1.4 million in net income, and $1.18 million in operating cash flow.
• Achieved high gross margins exceeding 70% in H1 fiscal 2026, indicating a strong and efficient business model.
• CEO's significant cash-acquired shareholding of over 122 million shares demonstrates strong alignment with shareholder interests and confidence in the company's future.
• Strategic focus on scaling businesses into durable, cash-generating machines across multiple sectors.
• Expansion into the veterinary market through Peaks Curative's acquisition of Zoolzy.com.
• Expansion into the premium American-made BBQ tool brand market through MagneChef's acquisition of BBQraft.

Negatives

• Hayden IR noted that current financial numbers 'mask significant operating leverage' and that a 'simple rationalization of expenses points to a much higher earnings baseline,' implying current operational efficiency could be improved to unlock greater earnings potential.

Risks

• Risks related to the markets for the company's products and services.
• Fluctuations in costs of goods and services.
• Impact of other operating expenses.
• Changes in government regulations affecting its diverse operations.
• Potential litigations.
• General business conditions and economic downturns.

Future Outlook

The company aims to scale its businesses into durable, cash-generating machines, expand investor outreach and communications, and achieve scalable profitability. It plans to pursue licensure in additional U.S. states for its pharmacies and expand product lines for its direct-to-consumer brands.

Management Comments

• "We are pleased to partner with Hayden IR as we enter an important phase of growth and market repositioning." Giorgio R. Saumat, CEO and Chairman of Earth Science Tech.
• "With our regulatory foundation firmly established and our operations scaling across pharmacy, telemedicine, and direct-to-consumer channels, it is critical that the investment community clearly understands who we are today." Giorgio R. Saumat.
• "Hayden IR brings the experience, credibility, and capital markets expertise needed to help us communicate our strategy, performance, and long-term value proposition with clarity and consistency." Giorgio R. Saumat.
• "Earth Science Techs first half of fiscal 2026, marked by $17.8 million in revenue, $1.4 million in net income, and $1.18 million in operating cash flow, demonstrates a robust business model with gross margins exceeding 70%." James Carbonara, Partner at Hayden IR.
• "However, these numbers still mask significant operating leverage. A simple rationalization of expenses points to a much higher earnings baseline." James Carbonara.
• "With the CEO holding over 122 million shares acquired entirely with cash, the alignment is clear. Our mandate is to ensure investors recognize this verifiable path to scalable profitability." James Carbonara.

Industry Context

The engagement with a nationally recognized investor relations firm signals Earth Science Tech's intent to enhance its visibility and valuation in the capital markets, a common strategy for diversified holding companies with multiple operating segments (pharmacy, telemedicine, real estate, D2C) seeking to attract broader institutional and retail investor interest. The strong H1 2026 financial performance positions the company favorably within its various competitive landscapes, particularly with high gross margins in the healthcare and retail sectors.

Comparison to Industry Standards

• The reported gross margins exceeding 70% for H1 fiscal 2026 are notably strong, particularly for a diversified company operating in pharmacy, telemedicine, and direct-to-consumer retail. While specific comparable companies are not named in the filing, such margins are generally considered excellent across many industries and suggest strong pricing power or efficient cost structures within its operating segments. For instance, many pharmaceutical or specialized retail companies might aim for gross margins in the 40-60% range, making ETST's reported figures stand out.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased market awareness, improved valuation, and enhanced long-term value proposition due to strategic IR engagement and strong financial performance. The ongoing $10 million share repurchase program also benefits shareholders.
• Customers: Expanded access to compounding pharmacy services (RxCompoundStore.com, Mister Meds) and telemedicine platforms (Peaks Curative, DOConsultations), as well as new direct-to-consumer products (MagneChef).
• Employees: Growth and expansion across various subsidiaries may lead to increased opportunities and stability within the company.

Next Steps

• Hayden IR will develop and execute a comprehensive investor relations program, including investor messaging, outreach to institutional and retail investors, corporate access initiatives, and ongoing support around public disclosures and market education.
• Continued scaling of businesses across pharmacy, telemedicine, and direct-to-consumer channels.
• RxCompoundStore.com is actively pursuing licensure in remaining U.S. states.
• Mister Meds is currently applying for licensure in states not yet serviced by RxCompound.
• Peaks Curative aims to offer services nationwide through the development of its own healthcare provider network and ongoing licensure expansion for both pharmacies.
• MagneChef is in the process of expanding its product line for new offerings incorporating its intellectual property.

Key Dates

Recommendation

The company reported robust financial results for the first half of fiscal 2026, including significant revenue, net income, and operating cash flow, coupled with impressive gross margins exceeding 70%. The strategic engagement with Hayden IR, a recognized capital markets communications firm, signals a proactive effort to enhance market visibility and ensure investors fully recognize the company's value proposition and 'verifiable path to scalable profitability.' The CEO's substantial cash-acquired shareholding demonstrates strong alignment with shareholder interests. While the filing hints at unoptimized operating leverage, this is presented as an opportunity for future earnings growth. These factors collectively suggest a strong growth trajectory and a concerted effort to unlock shareholder value, making it an attractive investment.

Keywords

Earth Science Tech, ETST, Hayden IR, Investor Relations, Financial Performance, Compounding Pharmacy, Telemedicine, Real Estate Development, Direct-to-Consumer, H1 2026 Results, FINRA 15c-211, Corporate Governance, Share Repurchase